BIOFARMA GROUP acquired by ARDIAN
Context
Ardian acquired a majority stake in Biofarma Group from White Bridge Investments. Ardian's entry is designed to transform the European leader into a global champion, specifically targeting expansion into the US and APAC markets while maintaining its technological lead in the high-margin probiotic segment.
BIOFARMA GROUP, which reported an EBITDA margin of [members only] in 2022, is valued in this transaction at an EV/EBITDA multiple of Above 20x, representing a premium to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Biofarma Group is a leading European Contract Development and Manufacturing Organization (CDMO) for the nutraceutical and personal care industries. It specializes in the development, production, and packaging of food supplements, medical devices, probiotics, and cosmetics. The group is recognized for its high R&D capabilities and state-of-the-art production facilities.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
Above 20x
EV / EBIT
[members only]
Historical Financials (EUR)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2022 | FRESENIUS | MABXIENCE | SPAIN | CDMO |
| 02/2022 | MONTAGU PRIVATE EQUITY / PARTNERS GROUP | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 01/2022 | PERMIRA | KEDRION | ITALY | CDMO |
| 01/2022 | ANJAC BEAUTY & HEALTH | APOLLO HEALTHCARE CORP. | CANADA | CDMO |
| 01/2022 | PERMIRA | BIO PRODUCTS LABORATORY (BPL) | UNITED KINGDOM | CDMO |
| 12/2021 | THE CARLYLE GROUP / GTCR | RESONETICS | UNITED STATES | Medical Devices |
| 12/2021 | INTEGER | OSCOR | UNITED STATES | Implants & Prosthetics |
| 12/2021 | WINNCARE | PHARMAOUEST INDUSTRIES | FRANCE | Medical Devices |
| 12/2021 | PLANMECA GROUP | KAVO DENTAL | GERMANY | Medical Devices |
| 11/2021 | COLOPLAST | ATOS MEDICAL | SWEDEN | Medical Consumables |
Other operations with ARDIAN
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | ARDIAN | Munich Electrification | GERMANY | Batteries & EV Tech |
| 07/2026 | ARDIAN | Pflegia | GERMANY | Recruitment / Headhunting |
| 07/2026 | ARDIAN / EURAZEO / UBS | HR PATH | FRANCE | ERP, HR & Finance |
| 01/2026 | ARDIAN | IVB Wellness Lab | SPAIN | Nutrition & Dietary Supplements |
| 12/2025 | ARDIAN | Fermax | SPAIN | Safety & Security |
| 07/2025 | ARDIAN | Dovida | SWITZERLAND | Outpatient Care |
| 05/2025 | ARDIAN | MasterGrid | FRANCE | Electrical |
| 03/2025 | ARDIAN | AKUO | FRANCE | Renewables |
| 03/2025 | ARDIAN | DIOT-SIACI | FRANCE | Brokerage |
| 01/2025 | ARDIAN / EURAZEO / ASTORG | SYCLEF | FRANCE | HVAC (Heating/AC) |
REFERENCES
Valuation range: EV €1–10bn
Revenue range: €250–500M
EBITDA range: €50–100M
EV/Revenue range: 2x - 6x
EV/EBITDA range: Above 20x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BIOFARMA GROUP by ARDIAN are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: ardian